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The dual stimuli-controlled release of doxorubicin from gel-embedded nanoparticles is 
reported. Non-cytotoxic polymer nanoparticles are formed from poly(ethylene glycol)-b-
poly(benzyl glutamate) that, uniquely, contain a central ester link. This connection renders the 
nanoparticles pH-responsive, enabling extensive doxorubicin release in acidic solutions (pH 
6.5), but not in solutions of physiological pH (pH 7.4). Doxorubicin-loaded nanoparticles were 
found to be stable for at least 31 days and lethal against the three breast cancer cell lines tested. 
Furthermore, doxorubicin-loaded nanoparticles could be incorporated within a 
thermoresponsive poly(2-hydroxypropyl methacrylate) gel depot, which forms immediately 
upon injection of poly(2-hydroxypropyl methacrylate) in dimethyl sulfoxide solution into 
aqueous solution. The combination of the poly(2-hydroxypropyl methacrylate) gel and 
poly(ethylene glycol)-b-poly(benzyl glutamate) nanoparticles yields an injectable doxorubicin 
delivery system that facilities near-complete drug release when maintained at elevated 
temperatures (37 °C) in acidic solution (pH 6.5). In contrast, negligible payload release occurs 
when the material is stored at room temperature in non-acidic solution (pH 7.4). The system 












The design of effective methods to deliver anti-cancer drugs in a controlled manner is a key 
goal of medicinal chemistry.1 Materials which assist with drug encapsulation and distribution 
must prolong the circulation lifetime of drug molecules, and reduce the toxicity of free 
chemotherapeutic molecules on healthy cells.2 The development of innovative systems that can 
encapsulate appreciable drug concentrations, before releasing the drug at a targeted, or 
localised, site is essential for precise cancer treatment in the absence of side-effects.  
Polymeric nanoparticles are promising materials for drug delivery vehicles owing to their 
capability to encapsulate and distribute poorly water-soluble therapeutic molecules in vivo.3 
Polymers can also be designed to have sensitivity to a variety of stimuli; changes in 
environmental temperature4 and pH,5 the presence of a particular enzyme,6 light irradiation,7 
and the presence of a magnetic field can trigger payload release from polymeric particles.8 
Altered environmental pH is particularly relevant as an actuator for chemotherapeutic release 
as cancerous tissue (pH 5-pH 6.8) is more acidic than both healthy tissue and the blood (pH 
7.4).9 However, many nanoparticles proposed as potential drug delivery vehicles lack 
biodegradability in vivo, and long-term stability whilst stored prior to administration, rendering 
their practical application unworkable. Consequently, there is an urgent demand for polymer 
nanoparticles that preserve drug molecules within their structure for prolonged periods prior to 
administration, before releasing the therapeutic payload at a controlled rate at a target site upon 
injection (in vivo).   
Poly(α-amino acid)s (PAAs) are excellent candidates to be deployed as drug delivery vehicles. 
owing to their capability to readily self-assemble into discrete, stable, structures in solution.10 
In addition, PAAs are bio-derived, present a wide-range of functional groups, and offer 
biodegradability and biocompatibility.11 Ring-opening polymerisation (ROP) of α-amino acid 
N-carboxyanhydride (NCA) monomers produces PAAs in an efficient and controlled manner, 
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enabling the generation of block copolymers that can form materials for controlled release 
applications.12 However, there are currently no examples of PAA-based nanoparticles that 
undergo polymer backbone cleavage and drug release in response to acidic media, such as that 
presented by tumour tissue, owing to the stability of constituent amide bonds against acid-
mediated hydrolysis.  
The localised release of chemotherapeutic molecules from polymeric nanoparticles to the 
tumour site is essential to minimise cytotoxic effects on healthy tissue, and the resultant highly-
detrimental physiological side-effects. Polymer-based injectable gels which slowly release the 
therapeutic to the surrounding, target, tissue, offer an effective method to administer cytotoxic 
therapeutics in vivo.13 Recently, the creation of a poly(N-isopropylacrylamine)-based microgel 
enriched with the anti-HIV drug Lopinavir has been reported. Solid drug nanoparticles 
suspended within the in situ-forming implant enabled sustained drug release over four 
months.14 This acts as an excellent template for the creation nanoparticle-containing depot that 
forms upon injection into aqueous media, essential for nanoparticle immobilisation at the target 
site.  
In this work, a poly(benzyl-L-glutamate)-b-PEG (PBLG-b-PEG) block copolymer was 
produced that, crucially, contains an acid-sensitive ester bond between the polymeric blocks. 
Doxorubicin (Dox)-loaded PBLG-b-PEG nanoparticles maintained a stable dispersion with 
negligible Dox release in aqueous solution of pH 7.4. Conversely, extensive Dox release was 
observed when the nanoparticles were maintained in acidic solution (pH 6.5). In order to realise 
an injectable drug delivery system, Dox-loaded nanoparticles were entrapped within a 
thermoresponsive poly(2-hydroxypropyl methacrylate) (PHPMA) gel depot which prolongs 
nanoparticle residence time and controls their release at a target site. The combination of PAA-
based pH-responsive nanoparticles, and a thermoresponsive gel depot, offers a highly sensitive 
5 
 
injectable delivery system for the meticulously controlled delivery of chemotherapeutic 
molecules.  
 
2. Results and discussion 
2.1 Polymer Synthesis  
The hydroxyl group of MeO-PEG was used to initiate the BLG NCA ROP to afford an ester-
containing polymer, using MSA as the acid catalyst (Scheme 1). The amine group is 
protonated, restricting propagation, before DIPEA was added to trigger amine deprotonation 
and polymerisation. PBLG chain lengths of 2, 26 and 35, in PBLG-b-PEG113, were synthesised 
in order to produce nanoparticles of varied dimensions. The chemical structures and molecular 
weight of PBLG-b-PEG macromolecules were confirmed by 1H NMR spectroscopy and APC 
(Figures S1-S3 and Table S1). The extent of PBLG grafting from PEG was determined by 
normalising the proton environment that corresponds to the four protons of PEG (h in Figures 
S1-S3) and comparing the integration value to peaks that correspond to PBLG (a, b, c, d, i and 
g in Figures S1-S3). This data confirmed the successful preparation of the target block 
copolymers PBLG2-b-PEG113, PBLG26-b-PEG113 and PBLG35-b-PEG113. FTIR analysis was 
used to confirm the presence of expected ester (1742 cm-1, 1731 cm-1, 1650 cm-1 and 1743 cm-




Scheme 1. Reaction outline for the creation of PBLG-b-PEG nanoparticles that contain ester 
linkages to facilitate Dox release when stored in acidic solution.  
 
2.2 Nanoparticle Formation  
Nanoparticles were produced from the three polymer types by coacervation.15 DLS analysis 
revealed increased nanoparticle size with an increased proportion of hydrophobic PBLG within 
the block copolymer (Table 1). PDI values of PBLG2-b-PEG113 and PBLG26-b-PEG113 were 
less than, or close to 0.3, indicating the particle stability. PBLG35-b-PEG113 nanoparticles were 
considered unstable, after 21 days of storage due to the recorded PDI value (0.437). Therefore, 
PBLG2-b-PEG113 and PBLG26-b-PEG113 nanoparticles were chosen for drug release studies 
due to their appropriate size and PDI values after 21 days storage in aqueous solution. SEM 





Table 1. DLS data of PBLG2-b-PEG113, PBLG26-b-PEG113 and PBLG35-b-PEG113 
nanoparticles after 21 days. The hydrophobic content refers to the number of PBLG repeat 
units as a percentage of the total polymer repeat units. 
Copolymers Hydrophobic chain length 
(%) 
Size (nm) PDI 
PBLG2-b-PEG113 1.7 85 ±9 0.284 
PBLG26-b-PEG113 18.7 158 ±2 0.327 
PBLG35-b-PEG113 23.6 311 ±3 0.437 
 
The dimensions of Dox-loaded PBLG2-b-PEG113 and PBLG26-b-PEG113 nanoparticles were 
then measured by DLS (Table 2). In both cases the mean nanoparticle diameter was less than 
200 nm. The PDI values corresponding to PBLG2-b-PEG113 exceeded 0.3, but the PDI values 
corresponding to PBLG26-b-PEG113 nanoparticles remained less than 0.3, even after 21 days 
storage in solution.  
Table 2. DLS data revealing the size and stability of Dox-loaded PBLG2-b-PEG113 and 
PBLG26-b-PEG113 nanoparticles in water. 
Copolymers 
24 h 7 days 14 days 21 days 












94 ±5 0.478 93 ±4 0.681 91 ±7 0.533 86 ±8 0.618 
PBLG26-b-
PEG113 
160 ±11 0.234 162±16 0.225 160 ±18 0.231 161 ±19 0.233 
 
2.3 Dox Release Studies 
Dox release studies from PBLG2-b-PEG113 and PBLG26-b-PEG113 nanoparticles were 
performed in both pH 7.4 (PBS) and pH 6.5 (TRIS acetate) buffer solutions. Extremely limited 
loading efficiencies of 4.95% (loading per total polymer mass) were recorded for Dox 
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encapsulation within PBLG2-b-PEG113 nanoparticles in both pH 6.5 and pH 7.4 aqueous 
solution. In contrast, Dox loading efficiencies of 43.9% were recorded for PBLG26-b-PEG113 
nanoparticles in solutions of pH 6.5 and pH 7.4. Such enhanced drug loading may be ascribed 
to the more sizeable hydrophobic compartment that PBLG26-b-PEG113 nanoparticles present. 
Initially, Dox release was monitored from both nanoparticle sets at 37 °C. After 576 h, Dox 
release to pH 6.5 solution (38.6%, PBLG2-b-PEG113. 23.8%, PBLG26-b-PEG113) exceeded 
release to pH 7.4 solution (9.9%, PBLG2-b-PEG113. 0.96%, PBLG26-b-PEG113 (Figure 1). The 
rate of release into pH 6.5 buffer solution decreased over time, possibly due to Dox having to 
travel a greater distance increasingly from the nanoparticle core as time progressed, although 
release was very gradual; after 48 h Dox release from PBLG2-b-PEG113 nanoparticles was 
10.1% and release from PBLG26-b-PEG113 nanoparticles was 12.1%. The environmental 
temperature was increased after 576 h to 41 °C as cancer tumour tissue is slightly higher in 
temperature compared to healthy tissue in the human body,16 but Dox release was not 
significantly enhanced. The excessive release of Dox from PBLG2-b-PEG113 nanoparticles in 
pH 7.4 solution, coupled with limited Dox loading, rendered the nanoparticles imperfect as 
potential drug delivery vehicles. However, only 0.96 % of loaded Dox was released from 
PBLG26-b-PEG113 nanoparticles in pH 7.4 buffer solution after 744 hours; such negligible 
unwanted release makes this class of nanoparticle an excellent drug delivery vehicle candidate. 
In a pH 6.5 environment, 24 % of Dox was released progressively from PBLG26-b-PEG113 
nanoparticles after 744 hours, offering a system that permits prolonged drug release, 





Figure 1. i) Dox release from PBLG2-b-PEG113 nanoparticles in pH 6.5 and pH 7.4 








2.4 Cytotoxicity Analysis  
PBLG26-b-PEG113 nanoparticles that contained, or lacked, Dox were assessed against MCF-7 
breast cancer cells, triple-negative breast cancer cells (MDA-MB-231), and Her2-enriched (ER 
and PR negative) breast cancer cells (MDA-MB-453) in order to assess their ability to treat 
chemo-refractory disease. Free Dox was used as a positive control (Table S2). Negligible cell 
death was found for empty polymer nanoparticles at 37 °C for all types of breast cancer cells 
proving PBLG26-b-PEG113 nanoparticles to be non-toxic (Figure 2). Dox-loaded nanoparticles 
were assessed against the same three cancer cell lines, and significant cell death occurred with 
enhanced polymer concentration. Such nanoparticles were not as lethal as unloaded/free Dox 
added to the cell types at the same concentration, signifying the effective Dox encapsulation 
within, and continuous Dox release from, the nanoparticles. The difference in IC50 values 
between the polymer nanoparticles, Dox-loaded nanoparticles, and free Dox are significantly 
different for each cell line. 
The nanoparticles were assessed against non-cancer cell lines to determine if their therapeutic 
action was specific against cancer cells. HB2 and MCF10A normal breast cell lines were 
sensitive to Dox delivered via nanoparticle encapsulation and as free drug (Figure S6). 
Surprisingly, the polymer nanoparticles demonstrated some cytotoxic effect versus HB2 cells 
at concentrations of 10 µg/mL and greater, although further studies are required to determine 
if such extensive nanoparticle accumulation, and cell death, is likely to occur in vivo. Although 
the IC50s values were greater when nanoparticles were employed to encapsulate dox (4.485 
µg/mL (nanoparticle) vs. 0.201 µg/mL (free dox) for HB2 cells, 10.360 µg/mL (nanoparticle) 
vs. 0.391 µg/mL (free dox) for MCF10A cells), the action of the nanoparticles against non-





Figure 2. Cytotoxicity of PBLG26-b-PEG113 nanoparticles either empty (NPs) or loaded with 
Dox (Dox-Loaded NPs), and free Dox on three breast cancer cell lines. Serial dilutions of 
polymer or Dox-loaded polymer were incubated with i) MCF-7, ii) MDA-MB-231 (triple 




2.5 PHPMA200 Injectable Depot Creation 
In order to realise localised Dox release, a polymeric material capable of undergoing a solution 
to gel transition in aqueous solution was developed. PHPMA was identified as a suitable 
biocompatible polymer that could act as an injectable vehicle capable of forming a matrix in 
aqueous solution. Once formed, the matrix holds the nanoparticles specifically at the tumour 
site, limiting their access to healthy cells. The transformation of PHPMA from solution to gel 
phase was achieved by dissolving the polymer in DMSO, before injecting the solution into 
aqueous solution to form a scaffold maintained by polymer chain interactions (Figure S7). 
RAFT polymerisation featuring 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid (RAFT 
agent), AAPH (initiator) and HPMA was performed in an acetone/water mixture, yielding 
PHPMA with 80 and 200 repeat units. Polymer analysis via 1H NMR spectroscopy, FT-IR 
spectroscopy and APC (Figures S8-S10 and Table S4) confirmed successful PHPMA 
synthesis. PHPMA80 was unable to form stable gels, and therefore could not entrap dox-loaded 
PBLG26-b-PEG113 nanoparticles, in either pH 6.5 or 7.4 buffered solutions. However, 
PHPMA200 was able to form a depot that contains a vacant core and smooth surface in both 
aqueous solutions, and so was progressed to be used as the injectable depot (Figure S11).  
The suitability of PHPMA200 as an injectable depot capable of storing Dox-loaded 
nanoparticles was then determined. Free Dox or Dox-loaded PBLG26-b-PEG113 nanoparticles 
were added to a PHPMA200 solution in DMSO. A depot containing either free Dox or Dox-
loaded nanoparticles was then formed by injecting each solution into PBS buffer (Figure 3). 
PHPMA200 depot did not sequester free dox, resulting in considerable release of dox into the 
PBS buffer supernatant (pH 7.4) within 72 hours. Conversely, PHPMA200 depot that contained 
Dox-loaded PBLG26-b-PEG113 nanoparticles withheld the chemotherapeutic payload in PBS 





Figure 3. Comparison of free Dox and Dox-loaded PBLG26-b-PEG113 nanoparticles in 
PHPMA200 in PBS buffer solution. Both gels contain an equal mass of Dox; Free Dox loading 
= 0.063 mg of free Dox, and 0.46 mL of Dox-containing PBLG26-b-PEG113 nanoparticles in 
DMSO, with 43.9% loading efficiency, contain 0.063 mg of Dox. Details of this calculation 
are provided in the supporting information. 
 
The cytotoxicity of the PHPMA200 depot and PHPMA200 depot formed in the presence of 
Dox-loaded PBLG26-b-PEG113 nanoparticles were determined by injecting PHPMA and Dox-
loaded nanoparticles in DMSO, respectively, directly into cell culture medium that contained 
either MDA-MB-231 triple-negative breast cancer cells or HFFF2 fibroblast cells (Figure 4). 
This was conducted to determine the feasibility of applying the injectable material in vivo 
against normal and cancerous cells. The cell viability of MDA-MB-231 cells remained above 
88% after 48 h in all instances; cell viability against the PHPMA depot and the depot with 
Dox-loaded PBLG26-b-PEG113 nanoparticles incorporated was 88.4% after 48 h. At least 75% 
of HFFF2 fibroblast cells remained viable after 48 h in all instances; cell viability against the 
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PHPMA gel with Dox-loaded PBLG26-b-PEG113 nanoparticles included was 85.6% after 48 
h. A Two-way ANOVA test was conducted to determine statistical difference between 
samples/cell lines (Table S3). The results demonstrate the appropriateness of the system as 
an injectable material, particularly for the injection, localisation and potential long-term 
release of a chemotherapeutic at a tumour tissue site.        
 
 
Figure 4. Cell viability studies for the in situ formation of PHPMA gel, PHPMA with blank 
PBLG26-b-PEG113 nanoparticles incorporated, and PHPMA with Dox-loaded PBLG26-b-
PEG113 nanoparticles incorporated against i) MDA-MB-231 triple-negative breast cancer 
cells and ii) HFFF2 fibroblast cells.   
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2.6 Dox Release from Nanoparticles Embedded within an Injectable PHPMA200 Depot  
A detailed release study revealed the control over Dox release that the system presents. An 
insignificant amount of Dox was initially released from PBLG26-b-PEG113 nanoparticles in 
PHPMA200 gel that was maintained in both pH 6.5 acetate buffer solution and PBS buffer 
solution, either at room temperature or at 37 °C (Figure 5). 3.6% Dox release was recorded for 
the first 192 h when the nanoparticle-loaded gel was maintained in pH 6.5 solution at 37 °C. 
At this point, enhanced Dox release into the pH 6.5 environment commenced in studies 
conducted at both room temperature and at 37 °C. After 384 h, 84.2 % of Dox was released 
from gel stored in pH 6.5 solution at 37 °C. This compares to 40.7% release from gel stored at 
pH 6.5 at room temperature. Whilst at this time point the depot was intact, it may be surmised 
that sufficient PHPMA200 disassembly had occurred to enable increased interaction between 
pH 6.5 buffer solution and nanoparticles that have increased mobility, enabling nanoparticle 
fragmentation and consequent Dox release. When the nanoparticle-loaded gel was maintained 
in solution of pH 7.4, insignificant Dox release occurred after 500 h, whether the material was 
heated to 37 °C or not. It can be concluded that Dox release from the reported injectable system 
is highly sensitive to environmental pH, the extent of release can be modified by changes in 
external environmental temperature, and that long-term storage (> 500 h) of Dox within 
nanoparticle encased gels can be realised. The system offers both rapid Dox release (freely-
loaded Dox in the PHPMA200 depot), and prolonged Dox release from acid-sensitive 




Figure 5. Dox release from PBLG26-b-PEG113 nanoparticles embedded within PHPMA200 
depot formed in pH 6.5 acetate buffer solution and pH 7.4 PBS buffer solution, at room 
temperature and at 37 °C.  
 
3. Conclusion 
pH-Responsive PBLG-b-PEG polymer nanoparticles were synthesised via hydroxyl-initiated 
NCA ROP. The nanoparticles were well separated and stable in pH 7.4 aqueous environment 
after 21 days, as revealed by DLS analysis. In a pH 6.5 aqueous environment, a considerable 
amount of Dox (24 %) was released from PBLG26-b-PEG113 nanoparticles after 31 days due to 
the intended hydrolysis of the ester links that are an essential feature of nanoparticle design. 
Crucially, a negligible amount of Dox was released from the nanoparticles when they were 
maintained in aqueous solution of pH 7.4 after 31 days (0.96 %), suggesting that the 
formulation may be stored in solution for prolonged periods prior to clinical deployment, an 
important, but often overlooked, feature of any potential drug delivery system. PBLG26-b-
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PEG113 nanoparticles were non-toxic against a variety of breast cancer cell lines, but Dox-
loaded PBLG26-b-PEG113 nanoparticles were toxic against the same breast cancer cells. In order 
to provide a vehicle that enables nanoparticle injection and perpetuation at a cancerous site, a 
PHPMA200 depot was developed that formed upon injection into aqueous solution. A limited 
amount of Dox was released from Dox-loaded PBLG26-b-PEG113 nanoparticles that were 
withheld within PHPMA200 depot that was maintained within PBS buffer solution, both at room 
temperature and 37 °C. Dox release was enhanced from the same material when stored in pH 
6.5 acetate buffer solution at both room temperature (44.7 %) and 37 °C (84.2%) after 16 days. 
The combination of pH-responsive PBLG26-b-PEG113 nanoparticles and a thermoresponsive 
PHPMA200 gel depot yields a highly-sensitive injectable delivery system that may be deployed 
for the localised, highly-controlled and prolonged release of Dox at cancer tumour sites. 
 
4. Experimental Section  
4.1 Materials and methods 
Methanesulfonic acid (98+ %), N-ethyldiisopropylamine (99 %), tetrahydrofuran and TRIS 
acetate 1.0 M buffer solution pH 6.5 were purchased from Alfa Aesar. Chloroform (99.9 %, 
extra dry over molecular sieve, stabilised, acroseal) was obtained from ACROS Organics. 
Triethylamine anhydrous, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid and 
doxorubicin hydrochloride were obtained from Fluorochem Incorporation. Poly(ethylene 
glycol)methyl ether (average Mn 5,000), chloroform-d (99.8 atom % D) 2,2’-azobis(2-methyl-
propionamidine) dihydrochloride (AAPH), dialysis tubing benzoylated 2000 Da and phosphate 
buffered saline tablets were obtained from Sigma-Aldrich Corporation. Dimethyl sulfoxide 
(99.80 % D) was purchased from EURISO-TOP. Diethyl ether (analytical reagent grade) and 
triethylamine were obtained from Fisher Scientific International Incorporation. Acetone was 
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purchased from VWR chemicals. BLG NCA and hydroxypropyl methacrylate were obtained 
from previous PhD students and school of engineering of University of Leeds, respectively.   
Nuclear magnetic resonance spectroscopy (NMR, Bruker AVANCE III HD500) and 
Attenuated total reflection (ATR-PLATINUM) fourier-transform infrared spectroscopy (FTIR, 
BRUKER ALPHA) were employed to analyse chemical structures, functional groups and chain 
lengths of the synthesised polymers. Advanced Polymer Chromatography (APC) was used to 
measure molecular weight of the synthesised polymers. APC was conducted on a Waters 
Acquity APC system using an Acquity column (Acquity APC TM 200 2.5 μm, 4.5 x 150 mm) 
and it calibrated against standard poly(methyl methacrylate) samples in tetrahydrofuran (THF). 
Particle size distribution of each synthesised polymer sample was measured via dynamic light 
scattering (DLS, Malvern Zetasizer Nano ZSP). Scanning electron microscopy (SEM, FEI 
NanoSEM 450) was used to analyse size and topography of nanoparticles. Drug release from 
polymer nanoparticles was measured via UV-vis spectroscopy (VARIAN 50 Probe UV-visible 
Spectrometer).    
 
4.2 Synthesis of PEG-b-PBLG 
The experiment was conducted as reported by Gradišar et al. under a nitrogen atmosphere.17 
Dry chloroform was degassed with nitrogen for one hour. 0.0412 g of BLG NCA, 0.1568 g of 
poly(ethylene glycol)methyl ether (Meo-PEG) (Mn 5000) and 6.0 μL of methansulfonic acid 
(MSA) were dissolved in 5.0 mL of dry chloroform. The reaction was stirred in an oil bath at 
40 °C for 24 hours. Then the reaction mixture was cooled to room temperature and put in an 
ice bath. 13 μL of N-ethyldiisopropylamine (DIPEA) was added into the reaction mixture. The 
reaction was stirred at room temperature without nitrogen atmosphere for 24 hours. Then the 
reaction mixture was added dropwise into cold diethyl ether. Next the solution was centrifuged 
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for 30 minutes at 4000 rev/ min and dried in a vacuum oven at 45 °C overnight. The product 
was dialysed against deionised water for 3 days, freeze dried for 2 days then white solids were 
formed. Different chain lengths of PBLG were prepared which were 2, 26 and 35. The 
experimental procedures were the same but used different amounts of reactants.  
Yield calculation: using molar ratio of reactants and products to calculate theoretical mass of 
products.  
Yield =  Actual mass of productTheoretical mass of product  × 100% 
 
4.3 Synthesis of PHPMA 
The reaction was in a sealed environment. 0.0297 g of 4-cyano-4-((phenylcarbonothioyl)thio) 
pentanoic acid was dissolved in 2.0 mL of acetone and 1.0 mL of deionised water. 0.2150 g of 
AAPH was added in the reaction followed by 1.0 mL of deionised water. When everything 
dissolved, 3.0521 g of HPMA was added into the reaction followed by 1.0 mL of deionised 
water. The reaction was stirred at 60 °C overnight and a cream colour gel was formed. Different 
chain lengths of PHPMA were prepared which were 80 and 200. The experimental procedures 
were the same but used different amounts of reactants. 0.103 g of PHPMA80 and PHPMA200 
gels were freeze dried, percentages of polymer in each gel were 36.4 % and 65.3 %, 
respectively.  
 
Supporting Information  
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Scheme 1. Reaction outline for the creation of PBLG-b-PEG nanoparticles that contain ester 













Figure 1. i) Dox release from PBLG2-b-PEG113 nanoparticles in pH 6.5 and pH 7.4 







Figure 2. Cytotoxicity of PBLG26-b-PEG113 nanoparticles either empty (NPs) or loaded with 
Dox (Dox-Loaded NPs), and free Dox on three breast cancer cell lines. Serial dilutions of 
polymer or Dox-loaded polymer were incubated with i) MCF-7, ii) MDA-MB-231 (triple 




Figure 3. Comparison of free Dox and Dox-loaded PBLG26-b-PEG113 nanoparticles in 
PHPMA200 in PBS buffer solution. Both gels contain an equal mass of Dox; Free dox loading 
= 0.063 mg of free Dox, and 0.46 mL of Dox-containing PBLG26-b-PEG113 nanoparticles in 
DMSO, with 43.9% loading efficiency, contain 0.063 mg of Dox. Details of this calculation 












Figure 4. Cell viability studies for the in situ formation of PHPMA gel, PHPMA with blank 
PBLG26-b-PEG113 nanoparticles incorporated, and PHPMA with Dox-loaded PBLG26-b-
PEG113 nanoparticles incorporated against i) MDA-MB-231 triple-negative breast cancer 








Figure 5. Dox release from PBLG26-b-PEG113 nanoparticles embedded within PHPMA200 
depot formed in pH 6.5 acetate buffer solution and pH 7.4 PBS buffer solution, at room 
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The acid-mediated, temperature-controlled, release of doxorubicin from poly(amino acid) 
particles embedded within a gel depot is reported. The particles are stable within aqueous 
solution, and able to withhold an anti-cancer therapeutic for prolonged periods in solution of 
physiological pH. This injectable system enables localised and controlled chemotherapeutic 
release to a mildly acidic environment, such as cancer tumour tissue.   
 
 
 
 
 
 
 
 
